TAISHAN-302 at a Glance
Design
Phase III, randomized 1:1, tambotatug pelitecan (B7-H3-directed ADC with topoisomerase-1 payload; MediLink Therapeutics, Roche license ex-China) versus topotecan in 451 patients with relapsed SCLC after platinum-based therapy. Presented by Prof. Li Zhang at the WCLC 2026 Presidential Symposium; simultaneously published in NEJM. (WCLC26 LBA 1840; NEJM)
Efficacy
Median OS 13.3 vs 9.4 months, HR 0.46 — a 54% reduction in the risk of death — with PFS HR 0.29 (95% CI 0.23–0.37) and significantly improved ORR, consistent regardless of baseline metastasis status or chemotherapy-free interval. (NEJM; WCLC26 presentation slides via KOL capture)
Safety
Grade ≥3 adverse events 55% vs 78% (treatment-related Gr≥3: 46.4% vs 74.7% per the presented slides) — fewer severe events with the ADC than with topotecan. The class toxicity to watch: ILD/pneumonitis in 4.9% vs 1.4%. (WCLC 2026 presented slides via verbatim physician captures on this page)
Regulatory status
⚠️ Tambotatug pelitecan is investigational — not approved anywhere. It holds U.S. FDA and China CDE Breakthrough Therapy Designations for relapsed SCLC. The investigators' presented conclusion: these results support Tam-Peli as a potential new standard-of-care option for second-line SCLC. (Roche media release Sept 13, 2026; IASLC press release)
KOL pulse
Ilyas Sahin (verbatim, on this page): “Longer survival, much higher response, and less severe toxicity ; a striking result in relapsed SCLC.” The sequencing question — where a B7-H3 ADC sits against DLL3-directed therapy in second line — ran through the physician threads.
KOLs Discussing TAISHAN-302
Key Slides & Data
What Physicians Said
🆙#WCLC26 #LCSM Plenary Session 🔥TAISHAN-302: Tam-Peli, an Anti-B7-H3 Antibody-Drug Conjugate, Versus Topotecan in Relapsed SCLC: A Randomized, Open-Label, Phase 3 Study 🎙️Dr. Li Zhang 🎯PFS HR 0.29 (95% CI 0.23-0.37) 🎯OS HR 0.46 (95% CI 0.35-0.62) 🔢PL02.03 ☑️NCT06612151 🔗 https://t.co/JvkpEBLlSo @OncoAlert @Larvol @IASLC
Dr. Li Zhang presents results from TAISHAN-302: phase III study of tambotatug pelitecan (tam-peli, YL201), a B7-H3 antibody drug conjugate (topo-1 payload, DAR 8) vs topotecan in relapsed SCLC at #WCLC26. Included pts with SCLC progressed after 1 line of platinum-based chemotherapy with a 1:1 randomization to tam-peli 2mg/kg q3w vs standard topotecan. Median f/u ~9m and 71 pts in tam-peli arm still on therapy (vs 8 with topotecan). Note that almost 30% of pts with no smoking history - a pattern we are seeing in ES-SCLC as well. Biology shifting...
Small-cell lung cancer is an aggressive cancer that often comes back after initial treatment. In phase 3 TAISHAN-302, tambotatug pelitecan (Tam-Peli) beat the standard chemotherapy topotecan: • Survival: 13.3 vs 9.4 months • PFS: 7.4 vs 2.8 months • Response: 59% vs 10% • Grade ≥3 side effects: 55% vs 78% Longer survival, much higher response, and less severe toxicity ; a striking result in relapsed SCLC. N=451. Interim analysis.
What a day for #SCLC! Two positive phase III ADC trials today at #WCLC26 ARTEMIS-008 and TAISHAN-302— and this may be just the beginning. Look at the pipeline 👇 The ADC era has finally arrived in SCLC. Bye bye, topotecan! 🚀 https://t.co/fjXfmHC7KL
#WCLC26 | TAISHAN-302 (1st interim) 📚 Simultaneously published in NEJM https://t.co/iyQXEIkVmA 🧬 Ph3: Tam-Peli (YL201), a B7-H3 ADC, vs topotecan in relapsed SCLC after 1 prior platinum line (n=451; ~87% prior IO) 🏆 OS: 13.3 vs 9.4 mo; HR 0.46 (95% CI 0.35–0.62, p<0.0001) 📉 PFS: 7.4 vs 2.8 mo; HR 0.29 🎯 cORR: 59.1% vs 9.7% 🧠 Intracranial activity: • PFS: 6.1 vs 4.2 mo; HR 0.43 • cORR: 32.4% vs 2.9% 🛡️ G≥3 TRAEs: 46.4% vs 74.7% ILD/pneumonitis: 4.9% vs 1.4%; no G4/5 👉 Marked OS/PFS benefit with systemic and CNS activity. Tam-Peli is a potential new standard for relapsed SCLC.
🚨 TAISHAN-302 | A major new option in relapsed SCLC Phase 3 data in NEJM: Tambotatug pelitecan (Tam-Peli), a B7-H3–targeted ADC, significantly outperformed topotecan after platinum-based therapy. 451 patients randomized 1:1 📌 Overall survival 13.3 vs 9.4 months HR 0.46 | P<0.001 📌 PFS 7.4 vs 2.8 months HR 0.29 | P<0.001 📌 ORR 59.1% vs 9.7% 📌 Grade ≥3 AEs 55.4% vs 77.9% Notably, intracranial response was 32% vs 3% in patients with baseline brain lesions. Why it matters: A B7-H3 ADC has now delivered a substantial survival benefit in a randomized phase 3 SCLC trial, with markedly improved response and PFS over topotecan. Limitations: Open-label study, investigator-assessed PFS/response, and enrollment restricted to China. Clinical verdict: Tam-Peli could become an important new second-line option for relapsed SCLC, adding a mechanistically distinct alternative alongside emerging DLL3-directed therapy. @ASCO @oncoalert #LCSM #SCLC #LungCancer
About the TAISHAN-302 Trial
Relapsed small-cell lung cancer after first-line platinum-immunotherapy has been topotecan territory for two decades, with modest benefit. TAISHAN-302 is the first phase III study of an antibody-drug conjugate to demonstrate statistically significant and clinically meaningful OS, PFS and ORR improvements over topotecan in this setting, per the investigators' presented conclusions. Tambotatug pelitecan (YL201, RG6919) targets B7-H3, broadly expressed on SCLC; MediLink Therapeutics developed it on its TMALIN linker platform, and Roche licensed it in January 2026 for development and commercialization worldwide outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials.
The WCLC 2026 debate centered on sequencing: the same Presidential Symposium carried ARTEMIS-008, a second positive phase III B7-H3 ADC readout in the same setting, and physicians immediately asked how the class fits against DLL3-directed therapy in second line. The enrollment was conducted in China; global applicability was a live discussion point in the KOL threads.
Trial Methodology & Results
Study Design
Phase III, randomized 1:1, open-label: Tam-Peli monotherapy vs topotecan, relapsed SCLC after platinum-based therapy. N=451, interim analysis. (NEJM; WCLC26 LBA 1840)
Population
Relapsed SCLC after prior platinum-based therapy (second line); enrolled in China. (NEJM; KOL discussion)
Endpoints
OS, PFS, ORR and safety; benefit reported regardless of baseline metastasis status or chemotherapy-free interval. (IASLC press release)
Presenter
Prof. Li Zhang — WCLC 2026 Presidential Symposium, LBA 1840; simultaneous NEJM publication.
Overall survival
Median OS was 13.3 vs 9.4 months in favor of tambotatug pelitecan, HR 0.46 (95% CI 0.35–0.62, p<0.0001 per KOL slide capture) — a 54% reduction in the risk of death at the interim analysis (DCO 20-May-2026 per the presented slides; median follow-up 9.2 months). (NEJM; WCLC 2026 presented slides on this page)
OS 13.3 vs 9.4 mo · HR 0.46Source: NEJM / WCLC 2026 LBA 1840 ↗
PFS, response and safety
PFS HR 0.29 (95% CI 0.23–0.37), median PFS 7.4 vs 2.8 months — a 71% reduction in the risk of progression — with ORR 59.1% vs 9.7% (Roche media release). Grade ≥3 adverse events occurred in 55% vs 78% (treatment-related Gr≥3 46.4% vs 74.7%); the trade-off to watch is ILD/pneumonitis at 4.9% vs 1.4% with the ADC. (WCLC 2026 presented slides on this page, DCO 20-May-2026; NEJM; Roche media release)
PFS HR 0.29 · Gr≥3 AEs 55% vs 78%Source: WCLC 2026 presentation slides (KOL capture) ↗
WCLC 2026: Live KOL Reaction
Physician posts about this trial captured live during the IASLC 2026 World Conference on Lung Cancer (Seoul, September 12–15). Quotes are verbatim; each card links to the original post. Last updated 2026-09-15.
We now have TWO studies showing B7-H3 ADCs vastly superior to standard topotecan for relapsed SCLC: tam-peli and ris-rez. These studies were different - different agents, different baseline demographics of pts, etc - but the outcomes were similar, control arms performed similarly. These trials reinforce each other. Looking forward to global studies and to first-line studies. The ADC era soundly here for SCLC and these will replace chemotherapy across lines, in my opinion. #WCLC26
🆙#WCLC26 #LCSM Plenary Session 🔥TAISHAN-302: Tam-Peli, an Anti-B7-H3 Antibody-Drug Conjugate, Versus Topotecan in Relapsed SCLC: A Randomized, Open-Label, Phase 3 Study 🎙️Dr. Li Zhang 🔢PL02.03 ☑️NCT06612151 🔗 https://t.co/icbDk1Zjnh @OncoAlert @Larvol @IASLC https://t.co/wIe6rP3BaM
TAISHAN 302 trial . HR of 0.29. Tam- Peli ( B7-H3 directed ADC ) vs Topotecan . Looks to be new SOC for second line SCLC ?? . How to put it in era of DLL3 targeting drugs ? @IASLC @StephenVLiu @RManochakian @OncoAlert @OncBrothers https://t.co/VGjzqbpd4P
🚨🔥@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @IASLC #WCLC26. ⭐️Results of #TAISHAN302 phase 3 trial of: #Tambotatug pelitecan (B7-H3 #ADC) vs #Topotecan in patients with #SmallCell #LungCancer after progression on 1st line platinum-based therapy. #Impressive results for #Tambotatug pelitecan: ✅⬆️ #mOS: 13.3 vs 9.4 months (#HR: 0.46) ✅⬆️ #mPFS: 7.4 vs 2.8 months (#HR: 0.46) ✅⬆️ #RR: 59.1% vs 9.7% ✅⬇️#Toxicity (≥ grade 3 # AEs: 55.4% vs. 77.9%) 👇🏻 https://t.co/avqw9sYa6v
TAISHAN-302 🔥 Tam-Peli vs topotecan in relapsed SCLC: OS: 13.3 vs 9.4 mo HR 0.46 | P<0.001 A 54% reduction in risk of death with a B7-H3 ADC. This is more than a response signal. This is a survival win. @ASCO @oncoalert #SCLC #LCSM https://t.co/nxI3dRkkvT https://t.co/gq4wFZWvEi
Major positive #WCLC26 result in relapsed SCLC: TAISHAN-302. Tambotatug pelitecan (Tam-Peli) vs topotecan: • OS 13.3 vs 9.4 mo, HR 0.46 • PFS 7.4 vs 2.8 mo, HR 0.29 • ORR 59.1% vs 9.7% • intracranial response 32% vs 3% • grade 3+ AEs 55.4% vs 77.9% My take: a major positive randomized phase 3 trial and a potential new 2L option in SCLC. Important caveat: this was a China-only study, so broader global validation still matters. Sequencing vs tarlatamab also remains an open question. #LungCancer #SCLC #ThoracicOncology #ClinicalTrials
Another ADC joins the SCLC armamentarium! Tam-Peli with huge OS, PFS and intracranial benefit over topotecan!! #WCLC26. Wonderful to have more options. Optimal choice of agent(s), sequencing, and resistance are areas of future investigation. @IASLC @SclcSMASHERS @drshieldsmd https://t.co/78orgwEKGA
TAISHAN-302 (Zhang L, et al) and ARTEMIS-008 (Wang J, et al) #WCLC26 @IASLC discussion by @Annechiangmd Take: Both phase 3 trials hit their primary OS endpoint vs topotecan with the same HR (0.46). TAISHAN-302: mOS 13.3 mo at 9.2 mo follow-up. ARTEMIS-008: mOS 18.5 mo at 12.2 mo follow-up. ILD/pneumonitis is the key safety. Cross-trial caveats are real: Chinese-only population, ~30% non smokers. IMO the activity should be similar in non Chinese. #SCLC #LCSM
🔥Waking up with another milestone in #SCLC coming from #WCLC26 🔵 @NEJM TAISHAN-302: B7-H3 ADC Tam-Peli vs topotecan after platinum ± IO (n=451, China). ➡️mOS 13.3 vs 9.4 mo (HR 0.46) mPFS 7.4 vs 2.8 (HR 0.29) ORR 59% vs 10% G≥3 AEs 55% vs 78% 💡OS ~tarlatamab, different mechanism 🤚China-only, open-label, short FU. @OncoAlert @oncodaily #LCSM
Tam-Peli, an anti-B7-H3 antibody-drug conjugate, versus topotecan in relapsed SCLC: A randomized, open-label, phase 3 study (TAISHAN-302): Impresive efficacy and better tolerability with low ILD incidence. Quite robust data in Chinese population. Eager to see global data soon!! #WCLC26 #LCSM @IASLC
Dr. Li Zhang presents the TAISHAN-302 Phase 3 study of Tam-Peli B7-H3 ADC (YL201) following at least one line of therapy compared to topotecan for ES-SCLC at @iaslc #WCLC26. Significant improvement in OS, PFS, ORR, and intracranial disease control. ILD 4.9% with YL201. This represents the Phase 3 with a B7-H3 ADC with improvement in outcomes over topotecan, however China only study. Publication is now available in NEJM today. It will be of great interest to understand how multiple B7-H3 available in pipelines will be of value to our patients impacted by SCLC globally. @SclcSMASHERS @LUNGevity @LungCancerEu @Lung_Cancers @OncoAlert @OncLive @StephenVLiu @lungoncdoc @RManochakian @OncBrothers
TAISHAN-302 at #WCLC26 In patients with relapsed SCLC, the B7-H3 ADC Tam-Peli significantly improved OS versus topotecan. Median OS: 13.3 vs 9.4 months HR 0.46 (95% CI 0.35–0.62), P<0.0001 A 54% reduction in the risk of death with Tam-Peli. #SCLC #LungCancer @OncoAlert @weoncologists @OpenMedKate @ManuelDomine
TAISHAN-302 Tam-Peli (B7H3 ADC) 2L SCLC Ph3, open label, v Topo ✅🔼OS 13 v 9m, HR 0.46 ✅🔼PFS HR 0.29 ✅🔼ORR 59 v 9% ✅🔼icRR 32 v 2% ✅🔽TRAEs 🤔 Remarkable efficacy Unprecedented OS in 2L SCLC Atypical SCLC popn, China only 💥A new SoC emerging Activity in 1L? #WCLC26 https://t.co/lrdMlnpGuU
Always love to see a drug beating topotecan. For #sclc. Tam-Peli (B7-H3 ADC) vs topotecan showed OS benefit (13.3 m vs 9.4 m, HR 0.46) with CNS efficacy. Safety profile seems a bit intense. High number of grade 3 or higher, most commonly hematologic. @IASLC #WCLC26 #ADC #lcsm https://t.co/4lQvjaAbjy
🔥 #WCLC26 #TAISHAN-302 🎯Tam-Peli (YL201), a B7-H3 ADC, vs topotecan in relapsed SCLC: ▶️ OS: 13.3 vs 9.4 mo; HR 0.46 ▶️ PFS: 7.4 vs 2.8 mo; HR 0.29 ⬆️ ORR: 59.1% vs 9.7% ⚠️Grade ≥3 TRAEs: 46.4% vs 74.7% ➡️An impressive 54% reduction in death and 71% reduction in progression but topitecan is a low bar and current landscape in the US includes tarlatamab ➡️Safety appears favorable vs topotecan with fewer grade ≥3 TRAEs, but Tam-Peli has important ADC-specific toxicities that require monitoring. @SclcSMASHERS @IASLC @OncoAlert #lcsm
ARTEMIS-008; Ris-Rez B7-H3 ADC; P3 RCT in relapsed SCLC v topo; n461; 87% ES-SCLC; WOW OS HR 0.46 in all subgroups :ORR 13%v 58%; ILD in 12% (4.9% in Tam-Peli TAISHAN 302);Await ex China global trial #WCLC26 https://t.co/HaS3TbnIH7
Published simultaneously with #WCLC26 in @NEJM: TAISHAN-302 shows markedly outperformed topotecan in relapsed SCLC after platinum therapy: • OS: 13.3 vs 9.4 mo (HR 0.46) • PFS: 7.4 vs 2.8 mo (HR 0.29) • ORR: 59.1% vs 9.7% • Gr ≥3 AEs: 55.4% vs 77.9% @OncoAlert @Larvol #sclc https://t.co/vTjYTKGn4U
#WCLC26 | TAISHAN-302 vs ARTEMIS-008 Two B7-H3 ADCs, identical OS HR 0.46 vs topotecan. Ris-Rez: mOS 18.5 mo; Tam-Peli: 13.3 mo, but cross-trial comparison is confounded by baseline risk. Class effect clear; winner still unknown.@OncoAlert https://t.co/0eIjOWzhat
Terrific discussion by #AnneChang at #WCLC2026 on ADCs in SCLC @IASLC TAISHAN-302 and ARTEMIS-008 both show clear OS/PFS benefit over topotecan, pointing to a possible new standard. Manageable toxicity overall Looking forward a bright ADC future 💡 https://t.co/NKTnmMi1pL
Two B7-H3 ADCs. Two positive phase 3 trials. One striking signal in relapsed SCLC. At WCLC 2026, TAISHAN-302 and ARTEMIS-008 both showed a major OS benefit over topotecan — remarkably, with an OS HR of 0.46 in each trial. • TAISHAN-302 — Tam-Peli: OS 13.3 vs 9.4 mo; PFS 7.4 vs 2.8 mo; ORR 59.1% vs 9.7% • ARTEMIS-008 — Ris-Rez: OS 18.5 vs 10.3 mo; PFS 7.2 vs 3.0 mo; ORR 58.3% vs 12.6% Both also showed substantially less grade ≥3 thrombocytopenia than topotecan. Important: this is a cross-trial comparison only. Different populations, study conduct and safety definitions mean we should not infer superiority of one ADC over the other. B7-H3 has arrived in relapsed SCLC. WCLC 2026 • PL02.03 TAISHAN-302 • PL02.04 ARTEMIS-008 #MVOnco #SCLC #B7H3 #ADC #LungCancer #WCLC2026 #Oncology #ThoracicOncology
Phase III Artemis study with Riz-Rez. Different ADC, same target. Almost the same results as TAISHAN-302. #LCSM #WCLC2026 https://t.co/apA8LMgsEa
🫁 A new second-line option for relapsed SCLC. #wclc26 TAISHAN-302 showed a major survival benefit with the B7-H3 ADC tambotatug pelitecan (YL201) vs topotecan: • OS: 13.3 vs 9.4 months, HR 0.46 • PFS: 7.4 vs 2.8 months, HR 0.29 • ORR: 59.1% vs 9.7% • Grade ≥3 TRAEs: 46.4% vs 74.7% OS benefit was consistent across subgroups, including brain and liver metastases and CTFI <90 days. #CánCare #SCLC #LungCancer #ThoracicOncology #ADC #B7H3
TAISHAN-302 is a randomised, open-label phase III study evaluating the efficacy and safety of Tam-Peli (2.0 mg/kg intravenously on day 1 of each 21-day cycle, maximum dose 200 mg) compared with topotecan in patients with small-cell lung cancer (SCLC) https://t.co/EUmSduaGr6
Results from phase III TAISHAN-302 study showing massive OS benefit of tam-peli over topotecan in relapsed SCLC @NEJM after #WCLC26 presidential. https://t.co/YK8fg3VK7w
Two B7-H3 ADCs presented at #WCLC26 produced very encouraging results in relapsed SCLC: ARTEMIS-008 (Ris-Rez) and TAISHAN-302 (Tam-Peli). We put them side by side in a descriptive cross-trial comparison. https://t.co/yjHAxmq7S1
🆙 #WCLC26 #LCSM Mini Oral Session 🔥 First-Line YL201 Plus Serplulimab in ES-SCLC and Advanced NSCLC: Phase 1 Results of a B7-H3-Directed Combination Strategy 🎯ES-SCLC: cORR 85.4%, DCR 92.7%, mPFS 12.9 mo 🎯Non-AGA NSQ-NSCLC: cORR 58.3% 🎯Squamous NSCLC: cORR 57.9% 🎯Grade≥3 TRAEs 38.8% 🎙️ Dr. H. Zhao 🔢 MO15.04 ☑️ NCT06394414 🔗 https://t.co/RyAjeLYzZC @OncoAlert @Larvol @IASLC
Dr. Jie Wang presents the ARTEMIS-008 Phase 3 results of Ris-Rez compared to topotecan in 2L+ ES-SCLC at @iaslc #WCLC26. Ris-Rez significantly improved OS, PFS, and ORR. ILD rate 11.7%. Fewer patients with platinum resistant disease (<90d) compared to Tam-Peli. Similar to YL201, China only study, but this study again demonstrates OS improvement over topotecan with a B7-H3 ADC. While highly effective initially, ADCs are prone to acquired resistance and cumulative myelosuppression that need to be proactively addressed. @SclcSMASHERS @LUNGevity @lungoncdoc @StephenVLiu @RManochakian @LauraAlderMD @NaglaAKarimMD @BrunaPellini @LungCancerEu @OncodailyLung @OncoAlert @OncLive
ADC have arrived in second line SCLC . Many options for patients now. Rapidly evolving field . Nice discussion to summarize both Taishan-302 and Artemis 008 . @IASLC @StephenVLiu @FordePatrick @CharuAggarwalMD @DrRiyazShah @LauraAlderMD https://t.co/Xm9cOOk6cO
Tam-Peli B7-H3 ADC; TAISHEN-302 P3RCTin relapse v topo ; open label; n451; median FU 9m; largely ES-SCLC; WOW OS curve in all subgroups; PFS HR 0.29! ;OSS 10% v 59%!; less toxic than chemo. I shan’t miss topotecan #WCLC26 https://t.co/HgRIvCE5jR
TAISHAN-302: B7-H3 enters the phase III SCLC arena. In relapsed SCLC after platinum-based therapy, tambotatug pelitecan (Tam-Peli) — a B7-H3–targeting ADC — beat topotecan across the major efficacy endpoints: OS: 13.3 vs 9.4 mo | HR 0.46 PFS: 7.4 vs 2.8 mo | HR 0.29 ORR: 59.1% vs 9.7% Grade ≥3 AEs: 55.4% vs 77.9% An encouraging intracranial signal was also seen: 32% vs 3% response, although this was exploratory. The message is bigger than response rate: this was an OS-positive randomized phase III trial. The next question may be just as important: where should a B7-H3 ADC sit alongside DLL3-directed tarlatamab? No head-to-head comparison yet. #MVOnco #TAISHAN302 #SCLC #LungCancer #B7H3 #ADC #TambotatugPelitecan #ThoracicOncology Reference: Zhao Y, et al. N Engl J Med. 2026. DOI: 10.1056/NEJMoa2610229.
TAISHAN-302, Li Zhang - potentially practice changing study in #SCLC. Topotecan is a crap drug, be good to see the end of it. Where this fits given Tarla data as maintenance also unclear. Suspect it will all come down to access. #LCSM #WCLC2026 https://t.co/yb5Gw4h4yl
#WCLC26 – A turning point for relapsed #SCLC? Two B7-H3 ADC trials vs topotecan: -TAISHAN-302: OS 13.3 vs 9.4mo (HR 0.46), ORR 59.1% vs 9.7% -ARTEMIS-008: OS 18.5 vs 10.3mo (HR 0.46), PFS 7.2 vs 3.0mo (HR 0.33) Big signals — potential new standard emerging @OncoAlert @Larvol https://t.co/jenXMESTTV
#WCLC26 Simultaneous publication @NEJM 👉🏽Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy | New England Journal of Medicine https://t.co/yOjmmyWNVC
TAISHAN-302: Phase 3 trial of Tam-Peli (B7-H3 ADC) vs topotecan in relapsed SCLC (N=451) after platinum therapy. OS: 13.3 vs 9.4 months (HR 0.46), 54% reduction in risk of death. Safety profile favorable and manageable #WCLC26 @IASLC https://t.co/4wJT1Pjpnv
#WCLC26 | ARTEMIS-008 Ris-Rez improved OS (18.5 vs 10.3 mo; HR 0.46) and PFS (7.2 vs 3.0 mo; HR 0.33) vs topotecan in relapsed SCLC. Another strong phase III signal for B7-H3 ADCs. How should we interpret this alongside TAISHAN-302? https://t.co/VRYS2dQXvH
TAISHAN-302 🔥 Tam-Peli vs topotecan in relapsed SCLC: OS: 13.3 vs 9.4 mo HR 0.46 | P<0.001 A 54% reduction in risk of death with a B7-H3 ADC. This is more than a response signal. This is a survival win. @ASCO @oncoalert #SCLC #LCSM https://t.co/gq4wFZWvEi
TAISHAN-302 (Zhang L, et al) and ARTEMIS-008 (Wang J, et al) #WCLC26 @IASLC Take: Both phase 3 trials hit their primary OS endpoint vs topotecan with the same HR (0.46). TAISHAN-302: mOS 13.3 mo at 9.2 mo follow-up. ARTEMIS-008: mOS 18.5 mo at 12.2 mo follow-up. ILD/pneumonitis is the key safety. Cross-trial caveats are real: Chinese-only population, ~30% non smokers. IMO the activity should be similar in non Chinese. #SCLC #LCSM
Dr. Li Zhang makes important clarification missed by some on TAISHAN-302: relapsed SCLC, tam peli with superior OS over topotecan. Though ~30% of patients had no smoking history, these are not transformed SCLC - those were excluded. This is a shift in SCLC biology we are seeing - and many are TP52/Rb1 intact. #WCLC26
Quick take from #WCLC26: Tam-Peli showed a clear overall survival advantage vs topotecan on the slide presented today: Median OS: 13.3 vs 9.4 months HR: 0.46 (95% CI 0.35–0.62) P < 0.0001 Reported as a 54% reduction in the rate of death Striking OS signal. More detailed thoughts soon. @iaslc #WCLC26 @oncoalert @oncodaily @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @latinamd @colazagasti @openmedicineHQ @asco @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @lungoncdoc @OncodailyLung @ClinicalLung #LCSM @LungPolicy #LungCancer #SCLC #ThoracicOncology
#WCLC26 | TAISHAN-302 In relapsed SCLC, Tam-Peli (YL201) significantly improved outcomes vs topotecan: OS 13.3 vs 9.4 mo (HR 0.46), PFS 7.4 vs 2.8 mo (HR 0.29), ORR 59.1% vs 9.7%, with meaningful intracranial activity. A strong candidate for a new standard in relapsed SCLC. https://t.co/BqRdRHQ2GO
🔥 #WCLC26 #TAISHAN-302 🎯Tam-Peli (YL201), a B7-H3 ADC, vs topotecan in relapsed SCLC: ▶️ OS: 13.3 vs 9.4 mo; HR 0.46 ▶️ PFS: 7.4 vs 2.8 mo; HR 0.29 ⬆️ ORR: 59.1% vs 9.7% ⚠️Grade ≥3 TRAEs: 46.4% vs 74.7% ➡️An impressive 54% reduction in death and 71% reduction in progression but topitecan is a low bar and current landscape in the US includes tarlatamab ➡️Safety appears favorable vs topotecan with fewer grade ≥3 TRAEs, but Tam-Peli has important ADC-specific toxicities that require monitoring. @SclcSMASHERS @IASLC @OncoAlert #lcsm
Wow. Tam-peli with a major improvement in OS over topotecan with median OS 13.3m vs 9.4m, OS HR 0.46. The curves split early, clear separation. Control arm performed as expected. Excellent outcomes in 2L setting. #WCLC26 https://t.co/kKQJPryCk9
3/6 TAISHAN-302 Tam-peli is a B7-H3 antibody-drug conjugate being compared with topotecan in relapsed SCLC. We know: Early-phase activity has been very encouraging. We don’t yet know publicly: whether the phase III trial is positive. At WCLC: OS, PFS, response durability and toxicity — and whether B7-H3 is truly ready for prime time in SCLC.
TAISHAN-302 FAQ
What is the TAISHAN-302 trial?
TAISHAN-302 (NCT06612151) is a phase III randomized trial of tambotatug pelitecan (Tam-Peli, YL201) — an investigational B7-H3-directed antibody-drug conjugate developed by MediLink Therapeutics and licensed by Roche in January 2026 for development and commercialization outside mainland China, Hong Kong and Macau — versus topotecan in 451 patients with relapsed small-cell lung cancer after platinum-based therapy. It was presented at the WCLC 2026 Presidential Symposium (LBA 1840) and simultaneously published in the New England Journal of Medicine.
What did TAISHAN-302 show?
Median overall survival was 13.3 versus 9.4 months in favor of tambotatug pelitecan (HR 0.46), with progression-free survival HR 0.29 (95% CI 0.23–0.37), a significantly higher response rate, and fewer Grade ≥3 adverse events than topotecan (55% vs 78%). Per the investigators, it is the first phase III ADC study to show significant OS, PFS and ORR improvements over topotecan in relapsed SCLC.
Is tambotatug pelitecan approved?
No. Tambotatug pelitecan is investigational and not approved by any regulator; it holds U.S. FDA and China CDE Breakthrough Therapy Designations for relapsed SCLC. The presented conclusions describe it as a potential new standard-of-care option for second-line SCLC, pending regulatory review.
How does TAISHAN-302 relate to ARTEMIS-008?
They are separate phase III trials of two different investigational B7-H3-directed ADCs, both presented at WCLC 2026 and both positive against topotecan in relapsed SCLC: TAISHAN-302 tested tambotatug pelitecan (MediLink/Roche) and ARTEMIS-008 tested risvutatug rezetecan (Hansoh/GSK). Together they were the meeting's headline validation of the B7-H3 ADC class.
What are the limitations discussed by KOLs?
Physicians flagged the open-label design, investigator-assessed PFS and response, enrollment restricted to China, and the sequencing question versus DLL3-directed therapies such as tarlatamab — including how B7-H3 ADCs and DLL3 T-cell engagers should be ordered in second-line SCLC.
Key KOL Sentiments
Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated September 13, 2026. Every statistic carries its source label in place; every quote is verbatim from the physician's own post.